文献库搜索 | GeneLibs

Abualsoud(BM),Alhomrani(M),Alamri(AS),Alsa... J Biomater Sci Polym Ed 2026-03-00

...BRCA1/2-mutated breast, ovarian, prostate, and pancreatic cancers. Despite their clinical success, challenges such as po...

Ouhajjou(A),Mazouji(O),Nejjari(C),Incitti(... Front Cell Dev Biol 2026-00-00

...BRCA1/2-mutated cancers and later in other HR-deficient tumors. PARP inhibitors have become essential components of firs...

Cavarzerani(E),Caligiuri(I),Bartoletti(M),... J Adv Res 2026-05-00

...BRCA1 mutation exhibited resistance to Carboplatin and PARP inhibitors, reflecting the clinical scenario and reinforcing...

Qian(J),Tanaka(K),Yasui(A),Ui(A) Commun Biol 2026-09-15

...BRCA1 and RAD51 to the DSB site. CHRAC promotes later RAD51-mediated HR steps through additional nucleosome-remodeling a...

Karakaya(G) Front Oncol None

...BRCA1/2 alterations are well-established predictive biomarkers for PARP inhibitor efficacy in several malignancies, thei...

Armon(S),Lieberman(S),Michaelson-Cohen(R),... JCO Precis Oncol 2026-04-00

...BRCA1/2 PV carriers: PS carriers received only post-test genetic counseling, whereas OC carriers received both pre- and ...

Blanc-Durand(F),Yaniz Galende(E),Ferron(G)... NPJ Genom Med 2026-04-23

...BRCA1/RAD51C promoter methylation assays, shallow whole genome and multiplex immunofluorescence. Homologous recombinatio...

Xu(C),Wang(D),Chen(R),Feng(X),Cheng(F),Che... Hematology 2026-12-31

...BRCA1 and RAD51. E2F7 silencing reversed Selinexor-induced HR suppression and DNA damage. In addition, Selinexor synergi...

Pollard(J),Parry(J),Wilkinson(T),Thompson(... Case Rep Oncol None

...BRCA1-mutant high-grade serous ovarian cancer underwent neoadjuvant chemotherapy followed by hysterectomy, bilateral sal...

Chailapakul(P),Maeda(J),Miura(T),Kato(TA) Mutagenesis 2026-08-27

...BRCA1 mutant cell line from Chinese hamster V79 cells and clarify the role of BRCA1 in the DNA damage response (DDR) by ...